Boehringer Mannheim Gmbh

Medibeacon Inc.

Roche Diagnostics Operations, Inc.

Cyanagen S.r.l.

Epis S.a.

Roche Diabetes Care, Inc.

Roche Diagnostics Gmbh

Roche Diagnostics International Ag

Norbert Gretz

F. Hoffmann-la Roche Ag

Ruprecht-karls-universitat Heidelberg

Johannes Pill

Daniel Schock-Kusch

Karlheinz Stegmeier

Christian Schildknecht

Soichi Watanabe

Ernst-Christian Witte

Wolfgang Wach

Felix Eickemeyer

Ralf Heinrich

Jae Hyung Hwang

Thomas Rose

Juergen Guenther

Stefan Koenig

Thomas Walter

Bernd Hagenbruch

Maliha Sadick

Jürgen Hesser

Sabine Neudecker

Otto Fuerst

Jacob Bar-Tana

Leopoldo Della Ciana

Federica Rodeghiero

Stefania Geraci

Jiaguo Huang

Zeneida Herrera Pérez

Stefanie Weinfurter

Jochen Friedemann

Bruno Dreckmann

Hans List

Herbert Harttig

Hans-Peter Haar

Ulrich Haueter

Uwe Kraemer

Rossana Perciaccante

Bernd Roesicke

Arnulf Staib

Hans P Wolff

Hans-Peter Wolff

Liesel Doerge

Peter Freund

Edgar Voss

Reinhard Kotulla

Bernd Rösicke

Johannes Aufenanger

Reinhard Heck

Jochanan Blum

Reiner Hegger

Hermann Eggerer

Tran G Nguyen

Jochen Friedmann

Karlheinz Stegmeir

Thomas Konrad

Klaus-Peter Junemann

Otto Fürst

Yoelit Migron

Carsten Deus

Jae Hyuug Hwang

Della Ciana Leopoldo Leopoldo

Hans-Martin Kloetzer

The present invention relates to a method for determining an organ function in a subject, comprising the steps of: providing a first concentration-time curve obtained by transcutaneously measuring in a body fluid at a first position background fluorescence in at least one first time point and fluorescence of an indicator compound in at least a second, a third, a fourth, a fifth, and a sixth time point; providing a second concentration curve obtained by transcutaneously measuring in a body fluid at a second position background fluorescence in at least one seventh time point and fluorescence of an indicator compound in at least a eighth, a ninth, a tenth, an eleventh, and a twelfth time point; fitting the first and the second concentration curve into a kinetic model representing at least four diffusion compartments; and thereby determining an organ function in a subject. The invention further relates to a device for determining an organ function according to the method of the present invention, said device comprising a first sensor for transcutaneously measuring fluorescence of an indicator at a first position, a second sensor for transcutaneously measuring fluorescence of an indicator at a second position; and a data processing unit for fitting the values obtained by the sensors into a kinetic model of one of the preceding claims. The present invention also relates to a kit comprising a device of the present invention and an indicator compound, as well as to a computer or computer network comprising at least one processor, wherein the computer or computer network is adapted to perform the method according to the present invention.

Transcutaneous organ function measurement

A sensor plaster () for the transcutaneous measurement of an organ function, more particularly of a kidney function, is proposed. The sensor plaster () comprises at least one flexible carrier element () having at least one adhesive surface () which can be stuck onto a body surface. Furthermore, the sensor plaster () comprises at least one radiation source, more particularly a light source (), wherein the radiation source is designed to irradiate the body surface with at least one interrogation light (). Furthermore, the sensor plaster () comprises at least one detector () designed to detect at least one response light () incident from the direction of the body surface.

The present invention relates to novel tricarbocyanine-cyclodextrin(s) conjugates useful as markers in the diagnosis of kidney diseases, a diagnostic composition comprising said conjugates, their use and their production.

Tricarbocyanine-cyclodextrin(s) conjugates and use thereof

Disclosed herein is a method for the transcutaneous determination of organ function in a subject. The method includes administering a fluorescent indicator substance to the subject, determining a first and a second concentration-time curve of the fluorescent indicator in a body fluid of the patient and fitting the concentration-time curves to a four compartment kinetic model.

A sensor device for detecting at least one analyte in a fluid, in particular in a body fluid, is disclosed. The sensor device includes at least one closed detector chamber and at least one electrical sensor having at least one sensor electrode. The detector chamber can be connected to the fluid in such a way that the analyte can penetrate into the detector chamber. The detector chamber includes at least one detector substance. The detector substance is designed to influence at least one electrical property of the electrical sensor, in particular at least one electrical property of the sensor electrode, depending on a concentration of the analyte in the detector chamber.

Sensor device for detecting an analyte

An introducing device for introduction of a medical device into a body is described which has a distal region with a tip region for generating an opening in the skin, and a segment region which comprises at least two sections which, in a rigid state, are essentially rigidly connected at least to one another and to the distal region and which are movable relative to one another in a flexible state. Furthermore, a system is described in which a sensor is integrated into the device for introduction into a body.

Flexible device for introducing a medical apparatus into a body

The invention relates to a method for investigating the glucose metabolism of a human being for disease-relevant and/or disease-related particularities. The glucose concentration g(t1) to g(tn) of a body fluid is measured at time points t1 to tn that are distributed over a period of at least six hours. The data points are then determined in phase space coordinates from the glucose concentration measuring values g(t1) to g(tn). The data points are then processed to highlight disease-relevant and/or disease-related particularities of the glucose metabolism of the investigated human being. The processing of the data points can be implemented by plotting them in a phase space representation or by determining from the data points a disturbance parameter that is correlated to the severity of a disturbance of glucose metabolism.

Method and system for investigating glucose metabolism

2,2-Dichloroalkanecarboxylic acids, processes for their production and

Use of .alpha., .omega.-dicarboxylic acids as fibrinogen sinkers

The present invention is concerned with the use of TXA.sub.2 receptor antagonists for the preparation of pharmaceutical compositions for the prevention of degenerative changes in penile tissue.

Method of preventing penile tissue degenerative change

The present invention provides compounds of the general formula: ##STR1## wherein E is an alkylene or alkenylene radical containing 2 carbon atoms, R.sup.1 is a cycloaliphatic hydrocarbon radical containing 5 to 12 carbon atoms, which is optionally substituted by up to 4 lower alkyl radicals, as well as halogen atoms, and can optionally be mono- or polyunsaturated, R.sup.2 and R.sup.3, which can be the same or different, are further cycloaliphatic hydrocarbon radicals containing 3 to 7 carbon atoms, hydrogen or halogen atoms, trifluoromethyl radicals or alkyl or alkoxy radicals containing up to 7 carbon atoms which can optionally also be substituted with methyl radicals, X is hydroxyl, Y is a residue of an alcohol or a residue of an amine or the group OZ, Z is hydrogen, an alkali metal or ammonium ion or X and Y taken together are --O--. Thus, these compounds are lactones or hydroxy acids of the formulae: ##STR2## wherein E, R.sup.1, R.sup.2 and R.sup.3 are as stated above, and Z is a hydrogen atom, and alkali metal ion or an ammonium ion; the esters and amides of the free carboxylic acids and the stereoisomeric forms thereof. The present invention also provides processes for the preparation of these compounds and pharmaceutical compositions containing them.

6-substituted-4-hydroxytetrahydropyran-2-one derivatives and

Growing community of inventors

Leimen, Germany

Johannes Pill